Nuvalent (NUVL) Stock Price, News & Analysis

Company Overview

Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets.

The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.

Key Stats

• Today's Range: $89.85 to $93.04
• 50-Day Range: $93.01 to $110.39
• 52-Week Range: $71.13 to $113.01
• Volume: 706,585 shs
• Average Volume: 599,642 shs
• Market Capitalization: $7.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $141.24
• Consensus Rating: Moderate Buy

Nuvalent Stock Analysis - MarketRank™

Nuvalent scored higher than 69% of companies evaluated by MarketBeat, and ranked 266th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 1 strong buy rating, 16 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Nuvalent has a consensus price target of $141.24, representing about 54.8% upside from its current price of $91.26.

Amount of Analyst Coverage

Nuvalent has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuvalent are expected to grow in the coming year, from ($5.74) to ($3.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvalent is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvalent is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvalent has a P/B Ratio of 5.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.54% of the float of Nuvalent has been sold short.

Short Interest Ratio / Days to Cover

Nuvalent has a short interest ratio ("days to cover") of 9.47.

Change versus previous month

Short interest in Nuvalent has recently decreased by 3.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvalent does not currently pay a dividend.

Dividend Growth

Nuvalent does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.12

News Sentiment

Nuvalent has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Nuvalent this week, compared to 5 articles on an average week.

Search Interest

1 people have searched for NUVL on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,828,337.00 in company stock.

Percentage Held by Insiders

5.02% of the stock of Nuvalent is held by insiders.

Percentage Held by Institutions

97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/03/2026
• Jefferies Global Healthcare Conference 2026: 6/04/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NUVL
• CIK: 1861560
• Web: www.nuvalent.com
• Phone: 857-357-7000
• Fax: N/A
• Employees: 40
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Nuvalent: $141.24
• High Price Target: $189.00
• Low Price Target: $105.00
• Potential Upside/Downside: +55.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$425.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.11%
• Return on Assets: -35.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.14
• Quick Ratio: 16.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.95 per share
• Price / Book: 5.69

Miscellaneous

• Outstanding Shares: 79,000,000
• Free Float: 75,032,000
• Market Cap: $7.17 billion
• Optionable: Optionable
• Beta: 1.15